Gilead Sciences, Inc. (GILD) Stake Lowered by Global Trust Asset Management LLC

Global Trust Asset Management LLC lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 9,832 shares of the biopharmaceutical company’s stock after selling 830 shares during the period. Global Trust Asset Management LLC’s holdings in Gilead Sciences were worth $615,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of the company. Sumitomo Mitsui Financial Group Inc. acquired a new position in Gilead Sciences during the 3rd quarter worth about $100,000. Reilly Financial Advisors LLC lifted its position in Gilead Sciences by 98.3% during the 3rd quarter. Reilly Financial Advisors LLC now owns 1,420 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 704 shares in the last quarter. North Star Investment Management Corp. lifted its position in Gilead Sciences by 11.5% during the 4th quarter. North Star Investment Management Corp. now owns 2,199 shares of the biopharmaceutical company’s stock worth $138,000 after buying an additional 226 shares in the last quarter. TRUE Private Wealth Advisors acquired a new position in Gilead Sciences during the 3rd quarter worth about $174,000. Finally, Vectors Research Management LLC acquired a new position in Gilead Sciences during the 3rd quarter worth about $178,000. Institutional investors own 78.01% of the company’s stock.

GILD has been the topic of several research reports. Zacks Investment Research downgraded shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 25th. ValuEngine raised Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Friday, September 28th. BidaskClub raised Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, September 29th. Cantor Fitzgerald assumed coverage on Gilead Sciences in a research note on Monday, October 1st. They set an “overweight” rating and a $87.00 target price for the company. Finally, Piper Jaffray Companies cut Gilead Sciences from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $85.00 to $75.00 in a research note on Friday, October 26th. Ten investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $88.39.

NASDAQ:GILD traded up $0.12 during trading hours on Friday, reaching $68.16. 5,591,773 shares of the stock were exchanged, compared to its average volume of 8,381,735. Gilead Sciences, Inc. has a twelve month low of $60.32 and a twelve month high of $89.54. The company has a quick ratio of 3.37, a current ratio of 3.45 and a debt-to-equity ratio of 1.09. The company has a market cap of $87.89 billion, a P/E ratio of 7.96, a price-to-earnings-growth ratio of -2.35 and a beta of 1.06.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. Gilead Sciences had a return on equity of 39.32% and a net margin of 7.12%. The firm had revenue of $5.60 billion during the quarter, compared to the consensus estimate of $5.44 billion. During the same quarter in the prior year, the firm posted $2.27 EPS. As a group, analysts anticipate that Gilead Sciences, Inc. will post 6.44 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Friday, December 28th. Shareholders of record on Friday, December 14th were given a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 3.35%. The ex-dividend date of this dividend was Thursday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is currently 26.64%.

In other news, Director John C. Martin sold 50,000 shares of the stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $71.20, for a total value of $3,560,000.00. Following the completion of the sale, the director now owns 2,877,762 shares of the company’s stock, valued at approximately $204,896,654.40. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 1.16% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Stake Lowered by Global Trust Asset Management LLC” was originally published by WKRB News and is the sole property of of WKRB News. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.wkrb13.com/2019/01/11/gilead-sciences-inc-gild-stake-lowered-by-global-trust-asset-management-llc.html.

Gilead Sciences Profile

Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Featured Article: What is a good rate of return for a mutual fund?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply